|
Metabolic Syndrome X
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken altogether, MME decreased metabolic syndrome and its complication via the increased PPAR-<i>γ</i> expression.
|
31182993 |
2019 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
The obtained results allow considering this compound as an interesting lead for the development of a new class of PPAR pan-agonists endowed with an activation profile exploitable for therapy of metabolic syndrome.
|
30996794 |
2019 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nowadays, novel PPARα drugs with broad safety margins and therapeutic potential for metabolic syndrome and cardiovascular diseases are being developed and applied in the clinical setting.
|
30562729 |
2018 |
|
Metabolic Syndrome X
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Supportingly, antibiotics prevented both downregulation of PPAR genes and the development of metabolic syndrome, while PPAR agonists prevented development of metabolic syndrome in TLR4<sup>ΔIEC</sup> mice.
|
29363671 |
2018 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
Low dose of clinical fibrates was effective against MS development independent of PPARα, and this action was mediated by STAT3 signalling inhibition in adipose tissue and, to a lesser extent, in hepatic tissues.
|
30251457 |
2018 |
|
Metabolic Syndrome X
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to establish associations between MetS-related abnormalities and the <i>PPAR-γ</i> rs1801282, <i>FTO</i> rs9939609, and <i>MC4R</i> rs17782313 polymorphisms.
|
29315078 |
2018 |
|
Metabolic Syndrome X
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The possible causes of metabolic syndrome by in-utero epigenetic alterations of genes involved in energy metabolism (PPARγ and PPARα), microRNAs, arginine methyltransferases, lysine demethylases, and histone deacetylaces have been elucidated.
|
27898587 |
2017 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the miR-21/PPARα axis was found amplified in liver and muscle biopsies, and in serum, of NAFLD patients, co-substantiating its role in the development of the metabolic syndrome.
|
28406477 |
2017 |
|
Metabolic Syndrome X
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The available relatives of the same family were interviewed (DSM-IV-R) and assessed in fasting conditions for body mass index, constituent variables of the metabolic syndrome (MS), leptin levels, insulin resistance index, and single nucleotide polymorphisms (SNPs) for the leptin receptor and promoter and PPAR-γ2 genes.
|
26083812 |
2016 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings indicate that IGFBP-2 might be a new target of metformin action in diabetes and the metformin-AMPK-Sirt1-PPARα-IGFBP-2 network may provide a novel pathway that could be applied to ameliorate metabolic syndromes by controlling IGF-1 bioavailability.
|
27009398 |
2016 |
|
Metabolic Syndrome X
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All PPAR SNPs were not associated with obesity and Met-S in the suburban population of Kampar, Malaysia, where only PPARα V162 and PPARγ2 T161 alleles were associated with plasma IL-6 and HOMA-IR, respectively.
|
26673968 |
2015 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of this chapter is to highlight the therapeutic benefits of targeting more than one PPAR subtype in the treatment of the metabolic syndrome.
|
24373239 |
2014 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results point to the use of PPAR and NR4A mRNA levels in the overall peripheral blood mononuclear cells as biomarkers of Metabolic Syndrome and bona fide putative targets of pharmacological therapy.
|
24060638 |
2013 |
|
Metabolic Syndrome X
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In previous studies, Pro12Ala polymorphism in peroxisome proliferator- activated receptors gamma 2 (PPAR-γ2) was shown to be associated with both longevity and metabolic syndrome, which was closely related with hyperuricemia.
|
21968942 |
2012 |
|
Metabolic Syndrome X
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The frequency distribution of rare alleles for PPARα (L162V) and PPARγ (P12A and H449H) was compared using the chi square test in 363 HIV-1-infected patients classified according to the presence or absence of the metabolic syndrome after 48 months of follow-up on their first PI-containing regimen.
|
21877956 |
2012 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review discusses the role and function of PPARs and their ligands in light of the metabolic syndrome.
|
18191967 |
2008 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
The high potency, significant gene induction, excellent PK profiles, and good in vivo efficacies in three animal models may render compound 24 as a valuable pharmacological tool in elucidating the complex roles of PPARalpha/delta dual agonists and as a potential treatment of the metabolic syndrome.
|
17608467 |
2007 |
|
Metabolic Syndrome X
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the PPARalpha-L162V polymorphism alone or in interaction with dietary fat intake is associated with components of the metabolic syndrome.
|
15309680 |
2004 |
|
Metabolic Syndrome X
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings support a role for the PPAR-gamma2 Pro12Ala variant in the etiology of type 2 diabetes and the insulin resistance syndrome.
|
11289057 |
2001 |